GLP-1 coverage in Pennsylvania
Medicaid no longer covers GLP-1s for obesity here. What that means, the indications that are still mandatory, and what it costs if you pay cash.
Updated 2026-09-18
Medicaid coverage of GLP-1s for obesity is optional for states under a long-standing statutory exception. Pennsylvania has exercised that discretion in a specific way.
Pennsylvania eliminated Medicaid coverage of GLP-1s for obesity treatment.
Pennsylvania dropped coverage of GLP-1s for obesity after October 2025. KFF also lists Pennsylvania among the states that cover one or more weight-loss drugs but do not cover any GLP-1 specifically — so a weight-loss benefit existing on paper does not mean a GLP-1 is available under it. Everything below is sourced — we are not going to tell you what a Pennsylvania clinic charges, because every provider we track is 50-state telehealth and prices the same wherever you live. What actually differs by state is coverage, and that is what this page is about.
Why Pennsylvania is different
Pennsylvania appears twice in KFF's analysis, and the two entries pull in different directions: it is listed among the four states that eliminated GLP-1 coverage for obesity after October 2025, and separately among the seven that cover one or more weight-loss drugs while covering no GLP-1. Read together they describe a state where a weight-loss benefit exists on paper and a GLP-1 is not available under it.
Medicaid and GLP-1s in Pennsylvania
Coverage for obesity is optional for states — the national picture is on our coverage index. Here is where Pennsylvania sits.
| Pennsylvania | |
|---|---|
| Status | Medicaid no longer covers GLP-1s for obesity here |
| Region | Northeast — regional adult obesity prevalence 30.3% |
| Board of pharmacy | Pennsylvania State Board of Pharmacy |
If you are on Medicaid in Pennsylvania
What to do in Pennsylvania: Ask specifically whether semaglutide or tirzepatide is on the formulary rather than asking whether weight-loss medication is covered. In Pennsylvania those questions have different answers.
Coverage for type 2 diabetes, cardiovascular disease and sleep apnea is mandatory everywhere, so a refusal framed around weight loss is not the end of it — and on Medicare, the $50 programme starts 1 July 2026 regardless of which state you are in.
Read next
- Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
- Who names their pharmacy
The hardest fact to get out of this market, and the one the FDA’s enforcement actually turns on. Here is who publishes it.
- Providers that work your insurance
Prior authorisations, appeals and coverage checks. For anyone whose plan might say yes, this is worth more than any discount.
- Trimi tirzepatide review
Lowest flat price with named pharmacies. What is actually dispensed, how the prescription works, and what the price really is — $125 a month.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure